Betnovate is a topical corticosteroid medication used for skin conditions. Its active ingredient is betamethasone which belongs to the class of synthetic glucocorticoids. The drug works by binding to intracellular corticosteroid receptors and modulating gene expression to reduce inflammation. This action suppresses the inflammatory cascade including cytokines prostaglandins and leukotrienes in the skin. The suppression of these mediators decreases redness swelling and itching associated with dermatitis and eczema. By reducing immune cell infiltration the medication also promotes faster resolution of lesions. The anti-inflammatory effect of betamethasone is responsible for its therapeutic role in controlling disease flare-ups. Overall Betnovate provides localized anti-inflammatory and immunosuppressive activity that alleviates symptoms without systemic consequences when applied as directed.

Betnovate is a topical corticosteroid formulation containing the synthetic glucocorticoid betamethasone dipropionate. It is formulated for application to the skin to reduce localized inflammation and irritation. The active ingredient penetrates the epidermis and binds to intracellular glucocorticoid receptors. This receptor-ligand complex translocates to the nucleus and modulates the expression of inflammatory genes. As a result the treatment decreases the production of inflammatory mediators such as cytokines and prostaglandins. The reduction of these mediators leads to a marked relief of redness, swelling, and itching in affected skin areas. Because the drug acts locally it provides targeted anti-inflammatory effects while minimizing systemic exposure. Betnovate is therefore utilized in the management of dermatological conditions that respond to topical corticosteroid therapy such as eczema, psoriasis, and dermatitis.

Betnovate may cause skin irritation at the application site. It can lead to dryness or flaking of the treated skin. Some users report a mild burning or stinging sensation upon use. Prolonged application may result in skin thinning or discoloration. Rarely it may trigger allergic reactions such as rash or itching. Systemic absorption is uncommon but can affect hormone levels in extensive treatment.

Betnovate may cause skin irritation such as redness or itching. It can lead to a burning or stinging sensation after application. Prolonged use may result in skin thinning or discoloration. Dryness or peeling of the treated area is also reported. Changes in skin pigmentation may occasionally occur. These effects are generally mild and often improve once treatment is stopped.